enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been given a consensus recommendation of “Buy” by the ten research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.22.
ENGN has been the topic of several analyst reports. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. Finally, Piper Sandler began coverage on shares of enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price objective on the stock.
Check Out Our Latest Stock Report on enGene
Hedge Funds Weigh In On enGene
enGene Trading Up 0.9 %
NASDAQ ENGN opened at $5.40 on Friday. The stock’s fifty day moving average price is $6.51 and its 200-day moving average price is $7.12. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $275.28 million, a P/E ratio of -9.31 and a beta of -0.61. enGene has a 12 month low of $4.42 and a 12 month high of $18.40.
enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. As a group, equities analysts forecast that enGene will post -1.56 EPS for the current fiscal year.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- Energy and Oil Stocks Explained
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.